All Search Results
News Releases
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Global commercialization driven by strategic alliancesIn January 2025, we entered into a partnership with Laboratorios Stein S.A. (SteinCares) to commercialize sugemalimab across ten countries in Latin America (LATAM). This was followed by a partnership with Istituto Gentili S.R.L. (Gentili)
More news about: CStone Pharmaceuticals
Feb 25, 2026, 18:54 ET SteinCares 與 Shilpa Biologicals 達成授權協議，致力擴大拉丁美洲生物相似藥的可及途徑
新的合作夥伴關係結合了 Shilpa Biologicals 的研發和生產能力，以及 SteinCares 的區域商業化平台合作目的在於擴大患者獲得具成本效益治療的可及途徑，並且鞏固 SteinCares 在拉丁美洲生物相似藥範疇的領導地位該協議標誌著這項策略合作關係的首個產品正式面世，同時宣告 Shilpa Biologicals 正式打入拉丁美洲市場哥斯達黎加聖荷西和印度賴久爾2026年2月26日
More news about: Shilpa Medicare Limited
Feb 25, 2026, 09:00 ET SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platformCollaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin AmericaAgreement marks the
More news about: Shilpa Medicare Limited
Feb 25, 2026, 04:00 ET SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platformCollaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin AmericaAgreement marks the
More news about: Shilpa Medicare Limited
Feb 25, 2026, 03:22 ET SteinCares và Shilpa Biologicals ký kết thỏa thuận cấp phép nhằm mở rộng khả năng tiếp cận thuốc sinh học tương tự trên khắp khu vực Mỹ Latinh
của Shilpa Biologicals với nền tảng thương mại hóa khu vực của SteinCaresSự hợp tác này nhằm mở rộng khả năng tiếp cận của bệnh nhân đối với các phương pháp điều trị tiết kiệm chi phí, đồng thời củng cố vị thế dẫn đầu của SteinCares trong lĩnh vực thuốc sinh học tương tự tại khu vực Mỹ LatinhThỏa
More news about: Shilpa Medicare Limited